{"id":839644,"date":"2026-08-02T10:58:37","date_gmt":"2026-08-02T10:58:37","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/839644\/"},"modified":"2026-08-02T10:58:37","modified_gmt":"2026-08-02T10:58:37","slug":"we-have-no-freaking-clue-what-weight-loss-drugs-are-doing-to-your-brain-warns-cambridge-professor","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/839644\/","title":{"rendered":"&#8216;We have no freaking clue&#8217; what weight-loss drugs are doing to your brain, warns Cambridge professor"},"content":{"rendered":"<p>The Caribbean island of St Kitts has a drinking problem. But it\u2019s not the people who like to overindulge \u2013 it\u2019s the island\u2019s vervet monkeys, who\u2019ve become notorious for sipping on cocktails stolen from tourists.<\/p>\n<p>A few years ago, however, <a href=\"https:\/\/scholar.google.com\/citations?user=taRZ6MgAAAAJ&amp;hl=da\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Prof Anders Fink-Jensen<\/a> travelled to St Kitts to see if he could learn something from the monkeys about helping humans to kick the habit. How? By giving them Ozempic.<\/p>\n<p>The University of Copenhagen psychiatrist discovered that, given free access to all the local rum they could guzzle, monkeys on the weight-loss drug drank significantly less than those given a placebo. Ozempic put a stopper in their drinking habits.<\/p>\n<p>Why? The short answer is we don\u2019t know, exactly. But we do know that, like the monkeys, some people on weight-loss jabs report drinking less.<\/p>\n<p>Users of semaglutide (the general name for Ozempic and similar medications) say they also smoke or vape less. And they report <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12770913\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">having fewer nagging thoughts<\/a> about food \u2013 otherwise known as \u2018food noise\u2019.<\/p>\n<p>But some users claim they\u2019ve been left feeling flat, joyless or just a bit \u2018meh\u2019 on GLP-1s, a feeling that\u2019s been labelled \u2018<a href=\"https:\/\/www.sciencefocus.com\/wellbeing\/feeling-just-meh-about-life-could-be-anhedonia\" rel=\"nofollow noopener\" target=\"_blank\">anhedonia<\/a>\u2019. This figures if, as scientists suspect, they curb addiction.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/08\/ozempic-vervet-monkeys.jpg\" alt=\"A vervet monkey drinks passion fruit juice from a plastic cup on a counter\" class=\"wp-image-216468\"\/>The vervet monkeys of St Kitts also had their lives changed when they started taking Ozempic &#8211; Image credit: Getty Images<\/p>\n<p>At the same time, evidence is building for possible benefits to a broad range of psychiatric and neurological problems, from depression to <a href=\"https:\/\/www.sciencefocus.com\/the-human-body\/dementia\" rel=\"nofollow noopener\" target=\"_blank\">dementia<\/a>.<\/p>\n<p>While some of this sounds positive, there\u2019s still so much we don\u2019t know. For a start, semaglutide and other drugs classed as GLP-1s are only really tested in people with diabetes or obesity.<\/p>\n<p>Would they be as safe and effective in those with mental health issues? How exactly do they work? And, crucially, how might they change our moods \u2013 and even our personalities?<\/p>\n<p>The race is on to find the answers. And with so many already on the jabs \u2013 an <a href=\"https:\/\/www.jpmorgan.com\/insights\/global-research\/current-events\/obesity-drugs\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">estimated ten million<\/a> in the US alone \u2013 there\u2019s a lot of people\u2019s mental health at stake.<\/p>\n<p>Life&#8217;s great pleasures<\/p>\n<p>Much of the evidence accumulated on weight loss drugs and mental health so far suggests they make us feel better. And, in a sense, that\u2019s exactly what we\u2019d expect.<\/p>\n<p>It seems obvious that those of us who spent years beating ourselves up about our extra baggage are going to feel better when we\u2019re suddenly able to slip into an old pair of jeans.<\/p>\n<p>University of Cambridge neuroendocrinologist <a href=\"https:\/\/www.wolfson.cam.ac.uk\/people\/giles-yeo\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Prof Giles Yeo<\/a> thinks so. \u201cLosing the weight already puts a positive spin on life,\u201d he says, agreeing that much of the benefit probably does come from the weight loss.<\/p>\n<p>But like others in the field, he\u2019s inclined to believe there\u2019s something else going on. Something tied up with the dopamine circuit \u2013 the <a href=\"https:\/\/www.sciencefocus.com\/the-human-body\/human-brain\" rel=\"nofollow noopener\" target=\"_blank\">brain<\/a>\u2019s reward system, which can get out of whack in addictive behaviours \u2013 that we don\u2019t quite understand yet.<\/p>\n<p>At the University of Oxford, psychiatrist <a href=\"https:\/\/www.psych.ox.ac.uk\/team\/riccardo-de-giorgi\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Dr Riccardo De Giorgi<\/a> and his team reckon they may be onto that something.<\/p>\n<p>They\u2019ve just finished a <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06363487\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">small study<\/a> in which 70 volunteers completed specially designed computer-based tasks one week after getting a jab of semaglutide. The tasks assessed, partly, the jab\u2019s effect on volunteers\u2019 reward processing \u2013 their motivation and willingness to put in the effort to \u2018win\u2019.<\/p>\n<p>The results aren\u2019t published yet, but De Giorgi says they may offer \u201cquite convincing evidence\u201d of how even a single shot of GLP-1s can affect the brain\u2019s reward system.<\/p>\n<p>Meanwhile, evidence for GLP-1s in action in those plagued by addiction continues to mount beyond monkey studies.<\/p>\n<p>In 2025, for example, a <a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/10.1001\/jamapsychiatry.2024.4789?utm_campaign=articlePDF&amp;utm_medium=articlePDFlink&amp;utm_source=articlePDF&amp;utm_content=jamapsychiatry.2024.4789\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">US team showed<\/a> in a clinical trial that semaglutide reduces alcohol cravings as well as the amount that heavy drinkers consume on their drinking days. And Fink-Jensen is due to publish results from <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05895643?tab=study\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">another trial<\/a> testing Wegovy (semaglutide) in heavy drinkers with obesity.<\/p>\n<p>But none of these studies reveal what GLP-1s are actually doing in the brain.<\/p>\n<p>If studies in lab rats and mice are anything to go by, then the suggestion is that they curb our appetite for addictive substances like alcohol, nicotine and cocaine by essentially reducing the hit \u2013 the chemical dopamine reward \u2013 that our brains get from them.<\/p>\n<p>As Fink-Jensen points out, though, such studies haven\u2019t been well-replicated in humans. \u201cWe thought we figured it out, but when we did it in humans the story [became] much more complicated,\u201d he says.<\/p>\n<p>It now seems unlikely it\u2019s as simple as so-called \u2018dopamine dampening\u2019, a phenomenon in which it\u2019s assumed a reduction in dopamine production saps enjoyment from food and, potentially, everything else.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/08\/ozempic-Hypothalamus.jpg\" alt=\"Illustration of the hypothalamus in the brain\" class=\"wp-image-216469\"\/>The hypothalamus is described as the brain\u2019s \u2018control centre\u2019 for regulating basic human functions &#8211; Image credit: Science Photo Library<\/p>\n<p>If weight loss drugs are doing anything in the dopamine circuit, it could be a concern because these neurons are considered the centre of our enjoyment in life\u2019s great pleasures, from food and drink to sex.<\/p>\n<p>But while there has been plenty of online chat about anhedonia \u2013 that feeling of joylessness, or loss of pleasure that\u2019s speculated to originate from dopamine dampening \u2013 Fink-Jensen argues this is all just hearsay.<\/p>\n<p>\u201cI don\u2019t think there\u2019s any evidence,\u201d he says. \u201cThere\u2019s been all this [talk] about libido and people\u2019s sex drives. Some people think that you will have these very slim, boring people who don\u2019t have any interest in anything in life. And that would be very sad, but there\u2019s no clinical data on it.\u201d<\/p>\n<p>De Giorgi, meanwhile, is slightly more cautious about dismissing claims of anhedonia and emotional blunting. \u201cIf some people are reporting it, then the chances are it\u2019s true. It\u2019s just that we don\u2019t know why person A and person B don\u2019t experience that, but person C does.\u201d<\/p>\n<p>Tentatively translating what seems to be happening with GLP-1s and \u2018food noise\u2019 to other things we enjoy, he suggests it\u2019s possible to imagine a full spectrum of responses people might experience.<\/p>\n<p>For example, the average person on Ozempic might say that their food noise becomes quieter. Not quiet enough that they don\u2019t enjoy their meals, but enough that they eat less.<\/p>\n<p>More rarely, people say their food noise is turned off completely, and this could also be true of other cravings, or anything that brings us pleasure. But these people would likely be outliers whose baseline noise level, for whatever vice, is already set very low.<\/p>\n<p>Interestingly, some people with ADHD also report anhedonia as <a href=\"https:\/\/carmenauthenticallyadhd.substack.com\/p\/adhd-and-anhedonia-when-motivation\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">a symptom of their ADHD<\/a> or medication. Whether this suggests any overlap between the brain circuits targeted by GLP-1s and ADHD medications is impossible to say, though, since \u2013 as Yeo emphasises \u2013 we don\u2019t know what they are.<\/p>\n<p>\u201cThis is why we need to know what\u2019s happening within the brain,\u201d he says.<\/p>\n<p>Read more:<\/p>\n<p>Drugs on the brain<\/p>\n<p>The main problem, according to Yeo, is that the drug companies have \u201cno freaking clue\u201d what GLP-1s are doing in our brains.<\/p>\n<p>\u201cThe more we know about how these drugs work, the more we can predict when something bad happens,\u201d says Yeo. \u201cSo, the more we know, the better. But we know very little.\u201d<\/p>\n<p>Yeo is now being funded by pharmaceutical company Amgen to find out how its own GLP-1 works. And his other recent studies involved slicing up human brains to <a href=\"https:\/\/apple.news\/AtZSoCwJvME65kksSthTk2g\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">map potential targets<\/a> for GLP-1s in the brain\u2019s \u2018control centre\u2019, the hypothalamus.<\/p>\n<p>We know that receptors for GLP-1s are plentiful in our brain\u2019s reward centre \u2013 the dopamine circuit. Though, as Yeo points out, the fact that the receptors are there is only \u201ccircumstantial\u201d evidence that GLP-1 drugs act on them.<\/p>\n<p>It could be that they\u2019re there to respond to natural GLP-1s produced locally in the brain, but that they can be hijacked by the synthetic mimics \u2013 the drugs.<\/p>\n<p>Right now, we know more about what the drugs do in the rest of our bodies. This includes our guts, where they mimic the natural GLP-1 <a href=\"https:\/\/www.sciencefocus.com\/the-human-body\/hormones\" rel=\"nofollow noopener\" target=\"_blank\">hormones<\/a> produced there that tell us we\u2019re full.<\/p>\n<p>Like the ones in our bodies, synthetic GLP-1s hit receptors that help regulate our blood sugar levels by driving up insulin production. It\u2019s insulin that shuffles sugar out of the bloodstream and into our cells. This is what\u2019s made GLP-1s so successful as diabetes drugs.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/08\/ozempic-treatment.jpg\" alt=\"A woman prepares for a subcutaneous self-injection with a semaglutide pen\" class=\"wp-image-216470\"\/>Weight loss drugs generally mimic the natural GLP-1 hormones in our bodies, but they work differently &#8211; Image credit: Getty Images<\/p>\n<p>But when it comes to satiety, the natural hormones work a little differently to the synthetic drugs. Natural GLP-1s notify the brain that we\u2019re full \u2013 but not by getting into the brain itself, which is relatively shut-off from the rest of the body.<\/p>\n<p>Besides, natural GLP-1s are broken down too quickly for that. \u201cThere\u2019s no way that the gut hormone versions of these survive long enough to get anywhere close [to the brain],\u201d says Yeo. Instead, they send messages via nerves in the gut.<\/p>\n<p>Which begs the question: how do synthetic GLP-1 drugs trigger the psychiatric and neurological effects scientists are now uncovering? By shooting up and into the brain somehow? Or by sending messages via the wider nervous system?<\/p>\n<p>It\u2019s an open question, because while it\u2019s not clear whether the drugs can penetrate the brain\u2019s safety systems, they do survive long enough to make it there.<\/p>\n<p>That\u2019s because they\u2019re not based purely on human hormones, but on <a href=\"https:\/\/www.nature.com\/articles\/s41392-024-01931-z\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">molecules from Arizona\u2019s infamous Gila monster lizards\u2019 venom<\/a>.<\/p>\n<p>These monster molecules, which break down in hours rather than minutes, were discovered in the 1990s and became the basis of the first approved GLP-1 drug, exenatide, for diabetes in 2005.<\/p>\n<p>All this time, scientists have largely relied on animal studies to tell them how GLP-1s might work in the brain. And yet, animal work doesn\u2019t necessarily translate into humans that well.<\/p>\n<p>Yeo\u2019s brain-slicing study demonstrated, for example, that we don\u2019t have GLP-1 receptors on all the same neurons as mice do.<\/p>\n<p>Plus, it\u2019s \u201cdifficult to access\u201d the human brain when it\u2019s alive, says De Giorgi. And, for most of the time we\u2019ve had GLP-1s, there hasn\u2019t been such a pressing need.<\/p>\n<p>\u201cThese medications have been around for a long time for non-psychiatric, non-neurological issues,\u201d he says. \u201cBut it\u2019s only now [they\u2019re being studied] with regards to mental health. So, there\u2019s a gap in knowledge.\u201d<\/p>\n<p>More good than harm?<\/p>\n<p>Thanks to the massive hike in use of GLP-1s for weight loss, however, things could change. In fact, US figures for 2023 show the number of non-diabetics using them <a href=\"https:\/\/www.bmj.com\/content\/386\/bmj.q1645.long\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">rising by 700 per cent<\/a> over just four years.<\/p>\n<p>What that means is scientists are suddenly gathering way more information about their effects on mental health, even if they don\u2019t understand exactly what\u2019s going on in the brain.<\/p>\n<p>Scientists have recently had to dig into all this new data to make sure the drugs aren\u2019t doing more harm than good.<\/p>\n<p>In 2023, the European Medicines Agency (EMA) <a href=\"https:\/\/www.ema.europa.eu\/en\/news\/ema-statement-ongoing-review-glp-1-receptor-agonists\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">raised red flags<\/a> over reports of self-harm and suicidal thoughts in a small number of people taking semaglutide and another GLP-1, liraglutide (also known as Saxenda).<\/p>\n<p>\u201cIt ended up that both the EMA and the Food and Drug Administration [in the US] said there was not a signal there,\u201d recalls Fink-Jensen, who himself <a href=\"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2823084\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">carried out a study<\/a> using data from Ozempic-maker Novo Nordisk to look into the issue.<\/p>\n<p>The study found no difference in rates of depression or suicidal thoughts and behaviour in people taking Ozempic versus those taking placebos.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/08\/ozempic-mental-health.jpg\" alt=\"Young woman sitting on sofa at home feeling sad, tired and worried, suffering depression in mental health\" class=\"wp-image-216472\"\/>There\u2019s still not enough evidence on the link between weight loss drugs and mental health, but it\u2019s growing &#8211; Image credit: Getty Images<\/p>\n<p>Broadly, what many of these new studies indicated was that the drugs have the opposite effect \u2013 that, rather than making mental health worse, GLP-1s improved it.<\/p>\n<p>One <a href=\"https:\/\/www.epicresearch.org\/articles\/most-glp-1-medications-correlated-with-a-lower-likelihood-of-anxiety-and-depression-diagnoses\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">non-peer-reviewed study<\/a> diving into the medical records of four million patients found that those on GLP-1s were less likely to be depressed.<\/p>\n<p>Meanwhile, <a href=\"https:\/\/www.thelancet.com\/journals\/lanpsy\/article\/PIIS2215-0366(26)00014-3\/fulltext\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">a recent Swedish study<\/a> focused on people with diagnosed depression who were taking GLP-1s for their diabetes. Again, it found they felt less depressed at times when they were on semaglutide or liraglutide.<\/p>\n<p>De Giorgi\u2019s <a href=\"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/article-abstract\/2833558\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">own recent review<\/a>, analysing results from studies involving over 100,000 people on the drugs for diabetes or weight loss, concluded that, overall, they improve quality of life. It also reported reductions in \u2018emotional\u2019 eating.<\/p>\n<p>What\u2019s more, in an earlier study, his team already ruled out negative impacts on 22 wide-ranging psychiatric and neurological complaints, from epilepsy to psychosis and obsessive-compulsive disorder to Parkinson\u2019s.<\/p>\n<p>They\u2019ve also picked out positive \u2018signals\u2019 in the case of nicotine addiction and dementia. What this means, De Giorgi explains, is that it\u2019s likely worth investigating the use of these medications for those conditions.<\/p>\n<p>That said, while GLP-1s have been consistently pushed as potential dementia drugs for the last two decades, <a href=\"https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=916462\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">early results<\/a> from a recent human trial by Novo Nordisk were disappointing.<\/p>\n<p>They showed that semaglutide did nothing to slow the progression of Alzheimer\u2019s disease over a two to three year period.<\/p>\n<p>It\u2019s possible that any dementia benefits may be thanks to the calming effect GLP-1s can have on blood sugar levels. When out of balance, these are associated with increased dementia risk.<\/p>\n<p>Reaping the rewards<\/p>\n<p>All this hints at the clear possibility that GLP-1s could treat a huge range of different conditions. That\u2019s exciting, because clinicians are desperate for new psychiatric treatments.<\/p>\n<p>But it\u2019s also worrying, because doctors may already be starting to take matters into their own hands to treat mental health issues, like depression, against scientists\u2019 advice.<\/p>\n<p>According to De Giorgi, this off-label prescribing is \u201cdefinitely happening,\u201d although probably more in private prescribing. Like Fink-Jensen, who has previously <a href=\"https:\/\/www.nature.com\/articles\/s41591-023-02634-8\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">issued stark warnings<\/a> about off-label prescribing of GLP-1s for alcohol use, he feels that doctors are jumping the gun and need to tread more carefully.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"800\" src=\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/08\/ozempic-prescription.jpg\" alt=\"Cropped shot of a chemist giving prescription to a customer in a pharmacy\" class=\"wp-image-216474\"\/>Officially, GLP-1 prescriptions are not currently designed for non-weight loss purposes &#8211; Image credit: Getty Images<\/p>\n<p>\u201cObviously, I\u2019m very excited about these medications,\u201d he says. \u201cI really wish that they could be helpful for a lot of patients, and perhaps for people with depression.<\/p>\n<p>\u201cBut, in reality, what we\u2019ve got so far is mainly data from people who are taking them not for depression. That data is reassuring, but we haven\u2019t looked at where risk actually lies.\u201d<\/p>\n<p>In other words, almost all of the data still comes from people with either obesity or diabetes. So, until researchers run bigger trials in people with \u2018just\u2019 depression, or \u2018just\u2019 addiction problems, we can\u2019t be sure what the psychiatric consequences might be in those groups of people.<\/p>\n<p>In any case, De Giorgi suggests, we still need to gauge whether the whole GLP-1 system \u2013 and whatever brain circuits it\u2019s hitting \u2013 is even a useful lever to pull on for mental health problems.<\/p>\n<p>If it is, then it won\u2019t be plain old Ozempic but a refined version of it we\u2019ll be using to treat depression. After all, not everyone who has depression, or a drinking problem, wants to lose weight.<\/p>\n<p>Eventually, a new generation of GLP-1 drugs designed with mental health in mind could be developed to hit multiple targets for better effect.<\/p>\n<p>It\u2019s an approach we\u2019re already starting to see with the triple-hitters (drugs that mimic three different hormones, not just GLP-1) that companies \u2013 like Mounjaro (tirzepatide)\u2019s maker, pharmaceutical company Eli Lilly \u2013 are now developing to enhance weight loss.<\/p>\n<p>Yet, while we lack a proper understanding of what GLP-1s are doing to our brains, we risk using them in ways that could still do serious harm.<\/p>\n<p>Clinical trials and even rum-swilling monkey studies might allow us to observe the behaviours, but they don\u2019t show us what it is in our own grey matter that causes them.<\/p>\n<p>Still, \u201cit\u2019s the best we can do,\u201d Fink-Jensen says, explaining that monkey brains are at least closer to human brains than rodent brains.<\/p>\n<p>\u201cHow much do we really know?\u201d he muses. \u201cTo my knowledge, there haven\u2019t been any good studies in human brains.\u201d<\/p>\n<p>The question is, he says: what\u2019s happening with the dopamine system? Let\u2019s hope we find out.<\/p>\n<p>Read more:<\/p>\n","protected":false},"excerpt":{"rendered":"The Caribbean island of St Kitts has a drinking problem. But it\u2019s not the people who like to&hellip;\n","protected":false},"author":2,"featured_media":839645,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[64,63,137],"class_list":["post-839644","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-au","tag-australia","tag-health"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/839644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=839644"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/839644\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/839645"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=839644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=839644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=839644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}